Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Epilepsy
Interventions: Cannabidiol (Epidiolex); Drug
Lead sponsor: Augusta University; Other
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Ankle Sprains
Interventions: MRX-7EAT, Placebo, Lidocaine, Etodolac; Drug
Lead sponsor: MEDRx USA, Inc.; Industry
Eligibility: 14 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 33
States / cities: Phoenix, Arizona • North Little Rock, Arkansas • Chico, California + 30 more

Conditions: Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II); Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 20
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 17 more

Conditions: Diabetic Foot Ulcer
Interventions: Tissue Engineered Skin Substitute, Offloading, Amnionic Membrane Graft; Procedure · Device
Lead sponsor: Professional Education and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Martinsville, Virginia • Roanoke, Virginia

Conditions: Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasm, Polycythemia Vera, Secondary Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib; Procedure · Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 3
States / cities: Columbus, Ohio • Portland, Oregon • Dallas, Texas

Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Neoplasms
Interventions: RO6895882; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Trauma Chest, Rib Fracture Multiple
Interventions: surgical stabilization, Usual care; Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 16 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Pain, Peripheral Neuropathy, Nervous System Diseases, Peripheral Nervous System Diseases, Peripheral Nervous System Problem, Peripheral Nerve Injuries, Peripheral Nervous
Interventions: StimRouter Neuromodulation System; Device
Lead sponsor: Bioness Inc; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 9
States / cities: La Jolla, California • Larkspur, California • Redwood City, California + 6 more

Conditions: Migraine Disorders
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions: Not listed
Lead sponsor: Accelerated Cure Project for Multiple Sclerosis; Other
Eligibility: Not listed
Enrollment: 3,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2036
U.S. locations: 10
States / cities: Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more

Conditions: CCSVI, Chronic Cerebrospinal Venous Insufficiency, Venous Malformations of CNS Draining Veins
Interventions: venous angioplasty; Procedure
Lead sponsor: Hubbard Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Downey, California • Oceanside, California • Atlanta, Georgia + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Placebo, ORMD-0801 QD, ORMD-0801 BD; Other · Drug
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Tustin, California

Conditions: Solid Tumors
Interventions: ALN-VSP02; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Benign Prostatic Hyperplasia, Overactive Bladder
Interventions: Mirabegron, Placebo, Tamsulosin Hydrochloride; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 715 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 32
States / cities: Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more

Conditions: Macular Edema, Diabetic
Interventions: Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more

Conditions: Type 2 Diabetes Mellitus
Interventions: PHX1149T; Drug
Lead sponsor: Phenomix; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 22
States / cities: Chula Vista, California • Fullerton, California • Long Beach, California + 19 more

Conditions: Arthritis, Unstable Radial Head, Proximal Radioulnar Joint Instability, Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
Interventions: Aptis PRUJ Prosthesis; Device
Lead sponsor: Aptis Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 7
States / cities: Carmel, Indiana • Louisville, Kentucky • Boston, Massachusetts + 4 more

Conditions: Diabetes, Cancer, Multiple Sclerosis, Arthritis, Parkinson's Disease, Cognitive Disorders, Brain Injury, Stroke
Interventions: Exergame, Home based balance training; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Acute Coronary Syndrome, Multi Vessel Coronary Artery Disease, Ischemic Stroke
Interventions: Life and Medication Recommendations; Behavioral
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: Talquetamab, Iberdomide, Dexamethasone, Bone Marrow Biopsy; Biological · Drug · Procedure
Lead sponsor: Alfred Chung, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide 7.5 mg; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 23
States / cities: Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more

Conditions: Nervous System Diseases, Diagnostic Imaging
Interventions: Ferumoxytol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Epidiolex and Drug Resistant Epilepsy in Children

MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains

PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors

Surgical Stabilization for Rib Fractures

StimRouter Registry Clinical Protocol

Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine

Biobank For MS And Other Demyelinating Diseases

Multi-center Registry for CCSVI Testing and Treatment

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

A Study to Evaluate Safety and Efficacy of PHX1149T in Subjects With Type 2 Diabetes Mellitus

Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.

Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures

Multidisciplinary Approach to Reduce Cardiovascular Health Disparities

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

MR, Histologic And EM Imaging Of Intravenous Ferumoxytol In Central Nervous System (CNS) Inflammation